Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 1
2011 10
2012 2
2013 3
2014 2
2016 3
2022 2
2023 1

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Leptin increases hepatic triglyceride export via a vagal mechanism in humans.
Metz M, Beghini M, Wolf P, Pfleger L, Hackl M, Bastian M, Freudenthaler A, Harreiter J, Zeyda M, Baumgartner-Parzer S, Marculescu R, Marella N, Hannich JT, Györi G, Berlakovich G, Roden M, Krebs M, Risti R, Lõokene A, Trauner M, Kautzky-Willer A, Krššák M, Stangl H, Fürnsinn C, Scherer T. Metz M, et al. Cell Metab. 2022 Nov 1;34(11):1719-1731.e5. doi: 10.1016/j.cmet.2022.09.020. Epub 2022 Oct 10. Cell Metab. 2022. PMID: 36220067 Free article. Clinical Trial.
Recombinant human leptin (metreleptin) reduces hepatic lipid content in patients with lipodystrophy and overweight patients with non-alcoholic fatty liver disease and relative hypoleptinemia independent of its anorexic action. ...In an independent cohort of lean men (n = 1 …
Recombinant human leptin (metreleptin) reduces hepatic lipid content in patients with lipodystrophy and overweight patients with non- …
Immunogenicity associated with metreleptin treatment in patients with obesity or lipodystrophy.
Chan JL, Koda J, Heilig JS, Cochran EK, Gorden P, Oral EA, Brown RJ. Chan JL, et al. Clin Endocrinol (Oxf). 2016 Jul;85(1):137-49. doi: 10.1111/cen.12980. Epub 2016 Feb 2. Clin Endocrinol (Oxf). 2016. PMID: 26589105 Free PMC article. Clinical Trial.
DESIGN: Two randomized controlled studies in patients with obesity (twice-daily metreleptin pramlintide for 20-52 weeks; 2006-2009); two long-term, open-label studies in patients with lipodystrophy (once-daily or twice-daily metreleptin for 2 months to 12.3 years; 2 …
DESIGN: Two randomized controlled studies in patients with obesity (twice-daily metreleptin pramlintide for 20-52 weeks; 2006-2009); …
Long-term metreleptin treatment increases bone mineral density and content at the lumbar spine of lean hypoleptinemic women.
Sienkiewicz E, Magkos F, Aronis KN, Brinkoetter M, Chamberland JP, Chou S, Arampatzi KM, Gao C, Koniaris A, Mantzoros CS. Sienkiewicz E, et al. Metabolism. 2011 Sep;60(9):1211-21. doi: 10.1016/j.metabol.2011.05.016. Epub 2011 Jul 7. Metabolism. 2011. PMID: 21741057 Clinical Trial.
Whether treatment with recombinant methionyl human leptin (metreleptin) for a long period improves BMD and BMC remains unknown. ...In subjects who completed the entire 2-year study (n = 4), metreleptin significantly increased BMD (P = .024) and BMC (P = .049) at the …
Whether treatment with recombinant methionyl human leptin (metreleptin) for a long period improves BMD and BMC remains unknown. ...In …
Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy.
Ravussin E, Smith SR, Mitchell JA, Shringarpure R, Shan K, Maier H, Koda JE, Weyer C. Ravussin E, et al. Obesity (Silver Spring). 2009 Sep;17(9):1736-43. doi: 10.1038/oby.2009.184. Epub 2009 Jun 11. Obesity (Silver Spring). 2009. PMID: 19521351 Free PMC article. Clinical Trial.

Combination treatment with pramlintide/metreleptin led to significantly greater weight loss from enrollment to week 20 (-12.7 +/- 0.9%; least squares mean +/- s.e.) than treatment with pramlintide (-8.4 +/- 0.9%; P < 0.001) or metreleptin (-8.2 +/- 1.3%; P < 0

…
Combination treatment with pramlintide/metreleptin led to significantly greater weight loss from enrollment to week 20 (-12.7 +/- 0.9 …
Efficacy of metreleptin in obese patients with type 2 diabetes: cellular and molecular pathways underlying leptin tolerance.
Moon HS, Matarese G, Brennan AM, Chamberland JP, Liu X, Fiorenza CG, Mylvaganam GH, Abanni L, Carbone F, Williams CJ, De Paoli AM, Schneider BE, Mantzoros CS. Moon HS, et al. Diabetes. 2011 Jun;60(6):1647-56. doi: 10.2337/db10-1791. Diabetes. 2011. PMID: 21617185 Free PMC article. Clinical Trial.
OBJECTIVE: Metreleptin has been efficacious in improving metabolic control in patients with lipodystrophy, but its efficacy has not been tested in obese patients with type 2 diabetes. ...We also observed for the first time that endoplasmic reticulum (ER) stress in human pr …
OBJECTIVE: Metreleptin has been efficacious in improving metabolic control in patients with lipodystrophy, but its efficacy has not b …
Selective capacity of metreleptin administration to reconstitute CD4+ T-cell number in females with acquired hypoleptinemia.
Matarese G, La Rocca C, Moon HS, Huh JY, Brinkoetter MT, Chou S, Perna F, Greco D, Kilim HP, Gao C, Arampatzi K, Wang Z, Mantzoros CS. Matarese G, et al. Proc Natl Acad Sci U S A. 2013 Feb 26;110(9):E818-27. doi: 10.1073/pnas.1214554110. Epub 2013 Feb 4. Proc Natl Acad Sci U S A. 2013. PMID: 23382191 Free PMC article. Clinical Trial.
Metreleptin restored both CD4(+) T-cell counts and their in vitro proliferative responses in these women. ...Our data show that metreleptin administration, in doses that normalize circulating leptin levels, induces transcriptional changes, activates intracellular si …
Metreleptin restored both CD4(+) T-cell counts and their in vitro proliferative responses in these women. ...Our data show that me …
Leptin administered in physiological or pharmacological doses does not regulate circulating angiogenesis factors in humans.
Aronis KN, Diakopoulos KN, Fiorenza CG, Chamberland JP, Mantzoros CS. Aronis KN, et al. Diabetologia. 2011 Sep;54(9):2358-67. doi: 10.1007/s00125-011-2201-x. Epub 2011 Jun 10. Diabetologia. 2011. PMID: 21660636 Free PMC article. Clinical Trial.
Serum was collected at 0, 6, 12 and 24 h after metreleptin administration. Twenty lean women, with leptin levels <5 ng/ml, were randomised in a 1:1 fashion to receive either physiological replacement doses of metreleptin (0.04-0.12 mg/kg q.d.) or placebo for 32 w …
Serum was collected at 0, 6, 12 and 24 h after metreleptin administration. Twenty lean women, with leptin levels <5 ng/ml, were ra …
The effect of leptin replacement on parathyroid hormone, RANKL-osteoprotegerin axis, and Wnt inhibitors in young women with hypothalamic amenorrhea.
Foo JP, Polyzos SA, Anastasilakis AD, Chou S, Mantzoros CS. Foo JP, et al. J Clin Endocrinol Metab. 2014 Nov;99(11):E2252-8. doi: 10.1210/jc.2014-2491. Epub 2014 Aug 22. J Clin Endocrinol Metab. 2014. PMID: 25148234 Free PMC article. Clinical Trial.
There was a trend toward a decrease in serum RANKL and increase in serum OPG in the metreleptin-treated group. The RANKL to OPG ratio was significantly decreased within the metreleptin (P = .04) but not the placebo group. Metreleptin had no effect on serum sc …
There was a trend toward a decrease in serum RANKL and increase in serum OPG in the metreleptin-treated group. The RANKL to OPG ratio …
Leptin Substitution in Patients With Lipodystrophy: Neural Correlates for Long-term Success in the Normalization of Eating Behavior.
Schlögl H, Müller K, Horstmann A, Miehle K, Püschel J, Villringer A, Pleger B, Stumvoll M, Fasshauer M. Schlögl H, et al. Diabetes. 2016 Aug;65(8):2179-86. doi: 10.2337/db15-1550. Epub 2016 May 10. Diabetes. 2016. PMID: 27207511 Clinical Trial.
The disturbed eating behavior can be restored by substitution with the leptin analog metreleptin. Long-term effects of metreleptin on resting state brain connectivity in treatment-naive patients with LD have not been assessed. ...Future studies need to assess whethe …
The disturbed eating behavior can be restored by substitution with the leptin analog metreleptin. Long-term effects of metreleptin …
Preadipocyte factor-1 levels are higher in women with hypothalamic amenorrhea and are associated with bone mineral content and bone mineral density through a mechanism independent of leptin.
Aronis KN, Kilim H, Chamberland JP, Breggia A, Rosen C, Mantzoros CS. Aronis KN, et al. J Clin Endocrinol Metab. 2011 Oct;96(10):E1634-9. doi: 10.1210/jc.2011-0600. Epub 2011 Jul 27. J Clin Endocrinol Metab. 2011. PMID: 21795455 Free PMC article. Clinical Trial.
DESIGN: Study 1 was a double-blinded, placebo-controlled randomized clinical trial of metreleptin administration in women with HA. Study 2 was an open-label study of metreleptin administration in low physiological, supraphysiological, and pharmacological doses in he …
DESIGN: Study 1 was a double-blinded, placebo-controlled randomized clinical trial of metreleptin administration in women with HA. St …
23 results

Searches related to "metreleptin"